Israeli study shows Pfizer vaccine 94 percent effective

EU regulator to decide on one-shot J&J vaccine next week

Credit: Pixabay/CC0 Public Domain

The European Medicines Agency said on Tuesday that it is set to decide whether to authorise Johnson & Johnson’s single-shot coronavirus vaccine for the EU on March 11.

If approved by the Amsterdam-based regulator, the vaccine would be the fourth to get the green light for the 27-nation bloc, in a boost for its slow-starting vaccination programme.

“EMA’s human medicines committee expected to give its recommendation for COVID-19 vaccine from Janssen on 11 March” at a special meeting, the watchdog said on Twitter.

Janssen-Cilag is the European subsidiary of US pharma giant J&J.

The EMA had previously said it expected to make a decision in mid-March, after Johnson & Johnson filed for approval on February 16.

The EU has so far approved three vaccines: Pfizer-BioNTech, Moderna and AstraZeneca-Oxford.

But the J&J would be the first that requires a single injection as opposed to two jabs, as well as being easier to store.

The Johnson & Johnson shot appears less protective than Pfizer and Moderna’s regimes, which both have an efficacy of around 95 percent against all forms of COVID-19 from the classic coronavirus strain.

Follow the latest news on the coronavirus (COVID-19) outbreak

© 2021 AFP

EU regulator to decide on one-shot J&J vaccine next week (2021, March 2)
retrieved 2 March 2021

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.